Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | TGM2 | P21980 | 1/20 | 0.64 |
| ▸ | HINT1 | P49773 | 4/20 | 0.61 |
| ▸ | PNP | P00491 | 1/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | KRAS | P01116 | 4/20 | 0.58 |
| ▸ | GSK3A | P49840 | 2/20 | 0.58 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.58 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.57 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.56 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanosine SCHEMBL2589323 | 0.96 | NT5E (0.72) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL1304255 | 0.96 | NT5E (0.72) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL376138 | 0.96 | NT5E (0.72) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL44407 | 0.96 | NT5E (0.72) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL94793 | 0.96 | NT5E (0.72) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL31361372 | 0.96 | NT5E (0.72) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL5356557 | 0.95 | NT5E (0.70) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL8719176 | 0.95 | NT5E (0.70) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL9238739 | 0.94 | NT5E (0.69) | NT5EHPGDTGM2HINT1PNP | |
| Guanosine SCHEMBL21315718 | 0.94 | HPGD (0.71) | NT5EHPGDTGM2HINT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223538-B2 | Post-synthesis labeling of nucleic acids, assays using nucleic acids that are labeled post-synthetically, single nucleotide polymorphism detection, and associated compounds and microarrays | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2007-05-29 | — | — | US | claimed |
| CN-1620515-A | Post-synthesis labeling of nucleic acids and uses thereof | AMERSHAM BIOSCIENCES AB (SE) | 2005-05-25 | — | — | CN | claimed |
| EP-1461455-A2 | POST-SYNTHESIS LABELING OF NUCLEIC ACIDS AND USES THEREOF | Amersham Biosciences AB (SE) | 2004-09-29 | — | — | EP | claimed |
| WO-2003052115-A2 | POST-SYNTHESIS LABELING OF NUCLEIC ACIDS AND USES THEREOF | AMERSHAM BIOSCIENCES AB (SE) | 2003-06-26 | — | — | WO | claimed |
| US-20030119005-A1 | Post-synthesis labeling of nucleic acids, assays using nucleic acids that are labeled post-synthetically, single nucleotide polymorphism detection, and associated compounds and microarrays | MOTOROLA, INC. | 2003-06-26 | — | — | US | claimed |
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | disclosed |
| EP-3047026-B1 | MULTIFUNCTIONAL RNA NANOPARTICLES AND METHODS OF USE | THE US SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20210162066-A1 | RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-06-03 | — | — | US | disclosed |
| US-20200199587-A1 | FUNCTIONALLY-INTERDEPENDENT SHAPE SWITCHING NUCLEIC ACID NANOPARTICLES | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-25 | — | — | US | disclosed |
| EP-3354734-B1 | OLIGONUCLEOTIDE-BASED INHIBITORS COMPRISING LOCKED NUCLEIC ACID MOTIF | MIRAGEN THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-10517890-B2 | Triggering RNA interference with RNA-DNA and DNA-RNA nanoparticles | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190192687-A1 | RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICE (US) | 2019-06-27 | — | — | US | disclosed |
| US-5962219-A | DETECTING NUCLEIC ACIDS WITH ACTIVITY BY MIXING WITH TARGET, FORMING COVALENT BOND BETWEEN TARGET AND CHEMICALLY REACTIVE UNIT OF NUCLEIC ACID, SEPARATING NUCLEIC ACIDS WITH ACTIVITY FROM NONREACTIVE NUCLEIC ACIDS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5858660-A | FORMING PRODUCT LIBRARY BY CONTACTING TWO OR MORE REACTANTS WHERE ONE REACTANT IS COUPLED TO NUCLEIC ACID CAPABLE OF MEDIATING BOND FORMATION, SELECTING PRODUCTS HAVING PREDETERMINED CHARACTERISTICS | NEXSTAR PHARMACEUTICLAS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5763595-A | NUCLEIC ACID LIGANDS WHICH BIND COVALENTLY WITH PROTEIN | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0840742-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: CHEMI-SELEX | NeXstar Pharmaceuticals, Inc. (US) | 1998-05-13 | — | — | EP | disclosed |
| US-5705337-A | NUCLEIC ACID DETECTION OF LIGANDS THAT BIND COVALENTLY WITH TARGET MOLECULE COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| EP-0782580-A1 | PARALLEL SELEX | NeXstar Pharmaceuticals, Inc. (US) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996027605-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: CHEMI-SELEX | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-09-12 | — | — | WO | disclosed |
| WO-1996009316-A1 | PARALLEL SELEX | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-03-28 | — | — | WO | disclosed |